Immunohistochemical staining of leptin is associated with grade, stage, lymph node involvement, recurrence, and hormone receptor phenotypes in breast cancer

Table 2 Correlation between high level of leptin immunoreactivity and clinicopathological parameters in the current study compared to previous studies

Previous studies	Leptin immunostaining prevalence in breast cancer cases	Leptin immunostaining prevalence in noncancerous breast tissue	Age	Size of tumor	Histotype	Grade	Stage	Recurrence	Lymph Node involvement	Hormone receptor phenotype (ER, PR, HER2)	ER expression	PR expression	HER2 expression	Vascular Invasion	Alive/Deceased status	Survival
The current study	83.7% (61% weak & 22.7% strong)	92.6% (51.9% weak & 40.7% strong)	P = 0.0233	NS	P = 0.0001	All grades low scores P = 0.0500	P = 0.0291	P = 0.0023	P = 0.0300	ER-, PR+, HER2-P = 0.0021	ER+ P = 0.0279	NS	P = 0.0021	NS	NS	Absent or Weak staining -Poor survival
[1]	100% (7.9% weak & 92.1% strong)	100% (100% weak)	NS	NS	NS		NS		NS		NS	NS				Overexpression – poor survival
[2]	60%	0%
[3]	86.4% (30.4% weak & 56% strong)	43.3% (43.3% weak)	NS	NS		High grade high scores P = 0.031			NS		NS
[4]							NS				NS	NS	NS			NS
[5]	79.6% (52.5% weak & 27.1& strong)	77.5% (50% weak & 27.5% strong)
[6]	79.6%			NS	NS	NS	NS		NS		NS	NS	NS	NS
[7]	85%	76.5%		NS							NS	NS
[8]	39%		NS			NS	NS			ER-, PR-, HER2-P = 0.022	NS	NS	NS			NS
[9]	83%			NS	P < 0.001	NS			NS		NS	NS	NS	NS
[10]	61%	40%									NS	NS	NS

ISSN: 1472-6874